AKT1 and prostate cancer: Studies have suggested that Digoxin possesses anti-proliferative properties against prostate cancer and breast cancer cells.[50] Digoxin demonstrates potential therapeutic benefits for non-small cell lung cancer in humans by inhibiting the phosphorylation of a protein kinase implicated in tumor cell survival, proliferation, metastasis, and autophagy within the PI3K/Akt pathway signaling.